Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response

被引:0
作者
Espen Molden
Cecilie Okkenhaug
Erik Ekker Solberg
机构
[1] Diakonhjemmet Hospital,School of Pharmacy
[2] University of Oslo,undefined
来源
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词
Anticoagulation; Bleeding risk; Cytochrome P450 enzymes; CYP2C9 variant alleles; Genotyping; VKORC1 haplotype; Warfarin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:525 / 530
页数:5
相关论文
共 132 条
[1]  
Hermans JJ(1993)Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics Br J Pharmacol 110 482-490
[2]  
Thijssen HH(1997)Human P450 metabolism of warfarin Pharmacol Ther 73 67-74
[3]  
Kaminsky LS(1997)Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers Biochem Pharmacol 54 1195-1203
[4]  
Zhang ZY(1998)Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes Clin Pharmacol Ther 63 519-528
[5]  
Yamazaki H(2003)Population differences in Clin Pharmacol Ther 73 253-263
[6]  
Shimada T(2001)-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients Clin Pharmacol Ther 70 159-164
[7]  
Takahashi H(2002)Interindividual variability in sensitivity to warfarin—nature or nurture? Clin Pharmacol Ther 72 702-710
[8]  
Kashima T(2004)Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance Pharmacogenetics 14 539-547
[9]  
Nomizo Y(2008)Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype Clin Pharmacokinet 47 565-594
[10]  
Muramoto N(2008)Pharmacogenetics of oral anticoagulants: a basis for dose individualization Pharmacotherapy 28 1084-1097